FUSCC Refractory TNBC Umbrella (FUTURE)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: Pyrotinib with Capecitabine|DRUG: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|DRUG: anti PD-1 with nab-paclitaxel|DRUG: PARP inhibitor included therapy|DRUG: BLIS with anti-VEGFR included therapy|DRUG: MES with anti-VEGFR included therapy|DRUG: mTOR inhibitor with nab-paclitaxel
Sponsor: Fudan University